Publications by authors named "M A Wetzler"

Radiolytically generated radicals cause degradation of nutrients in food, materials in satellites and solar cells, and human health. Radiation effects are studied using gamma radiolysis, a low-throughput, high-cost, and low-accessibility method. We developed a higher-throughput, low-cost, non-radioactive, radical assay that produces radicals similar to those generated in gamma radiolysis and examined monoamide degradation.

View Article and Find Full Text PDF

Purpose: To compare the pullout strength of a bio-inductive implant (BI) used to augment a medial patellofemoral ligament (MPFL) repair with the pullout strength of semitendinosus graft in a biomechanical cadaveric model.

Methods: Six matched pairs of cadavers (12 knees) were used in the biomechanical testing comparing semitendinosus tendon (Semi-T) versus a BI. The Semi-T was harvested from 1 of the matched pairs.

View Article and Find Full Text PDF
Article Synopsis
  • Meniscal injuries are common, and treating severe tears has led to advancements in meniscal scaffolds and implants over the past two decades.
  • Meniscal allograft transplant is currently a standard treatment for certain knee conditions, but issues like availability, costs, and sizing complicate the process.
  • New tissue-engineered implants show promise for short-term pain relief and function, but long-term effectiveness compared to allograft transplants is still uncertain.
View Article and Find Full Text PDF

Post-remission strategies after dasatinib-corticosteroid induction in adult Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) are not well studied. We evaluated dasatinib and dexamethasone induction then protocol-defined post-remission therapies, including hematopoietic cell transplantation (HCT). Adults (N = 65) with Ph-positive ALL received dasatinib-dexamethasone induction, methotrexate-based central nervous system (CNS) prophylaxis, reduced-intensity conditioning (RIC) allogeneic HCT, autologous HCT, or chemotherapy alone, and dasatinib-based maintenance.

View Article and Find Full Text PDF

Background: Rasburicase can markedly and rapidly decrease uric acid (UA) levels, thereby preventing and treating tumor lysis syndrome. However, rasburicase is expensive, especially when used as per the manufacturer's recommended dosage of 0.2 mg/kg/day for up to 5 days.

View Article and Find Full Text PDF